Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quinnova Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

Quinnova Pharmaceuticals Inc.'s Proderm Technology delivery system is a water-lipid-based formulation designed to apply active ingredients to the skin for the treatment of inflammatory skin diseases. Several Proderm products are already on the market. The start-up's TwinDerm technology - a two-step, single-unit topical system that allows delivery of two products in sequence from a single pouch - is designed to make treatment simpler and more convenient, therefore improving patient compliance.

You may also be interested in...



Start-Up Previews (03/2010)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Transdermal Drug Delivery: More Than Skin Deep, features profiles of AllTranz, Ocelus, Quinnova and Syntropharma. Plus these Start-Ups Across Health Care: Apnex Medical, Cellular Dynamics, Helix Therapeutics, Presym and Vatrix Medical.

Syntropharma Ltd.

Syntropharma Ltd. aims to take known drugs that can be improved via transdermal delivery, or gain product life-extension through reformulation in the novel delivery mechanism. The company is focusing on two candidates: a transdermal selegiline patch for depression (aimed at the European market) and a patch formulation of naltrexone, an opioid receptor antagonist for battling dependence on alcohol and opiates.

Ocelus Ltd.

Ocelus Ltd. hopes to extend transdermal delivery to macromolecules. Its early-stage technology combines a microchip reservoir with microneedles that could painlessly inject precise yet tiny amounts of a drug into the skin at hundreds of sites per square centimeter. This could make administration simpler, and by reducing the pain associated with injectable drugs, improve patient compliance.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT125711

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel